8K 11.7.13 ASH
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 7, 2013
Array BioPharma Inc.
(Exact name of registrant as specified in its charter)
|
|
Delaware |
(State or other jurisdiction of incorporation) |
|
|
| |
001-16633 | 84-1460811 |
(Commission File Number) | (I.R.S. Employer Identification No.) |
| |
|
| | |
3200 Walnut Street, Boulder, Colorado | 80301 |
(Address of Principal Executive Offices) | (Zip Code) |
|
(303) 381-6600 |
(Registrant’s telephone number, including area code) |
|
|
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
| |
__ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
__ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
__ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
__ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
In this report, “Array BioPharma,” “Array,” “we,” “us” and “our” refer to Array BioPharma Inc., unless the context otherwise provides.
Item 8.01 Other Events.
On November 7, 2013, Array BioPharma issued a press release announcing that data will be presented on two drug candidates, ARRY-520, a KSP inhibitor, and ARRY-614, a dual p38/Tie2 inhibitor, at the 2013 Annual Meeting of the American Society of Hematology (ASH).
A copy of the press release is attached to this Form 8-K as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
| | |
Exhibit No. | | Description |
99.1 | | Press Release announcing presentation of clinical data at the 2013 ASH Meeting on ARRY-520, a KSP inhibitor, and ARRY-614, a dual p38/Tie2 inhibitor |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| | | |
Date: November 7, 2013 | | Array BioPharma Inc. |
| | | |
| | By: | /s/ R. Michael Carruthers |
| | | R. Michael Carruthers |
| | | Chief Financial Officer |
| | | |
EXHIBIT INDEX
|
| | |
Exhibit No. | | Description |
99.1 | | Press Release announcing presentation of clinical data at the 2013 ASH Meeting on ARRY-520, a KSP inhibitor, and ARRY-614, a dual p38/Tie2 inhibitor |